OPPS Final Rule: 340B Softened, Imaging Cut Stays, NPIs Due

CMS released the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule on November 4, 2026, and the most-watched proposal came in softer than expected. 340B-acquired drugs will be paid at ASP minus 28%, not the ASP minus 33.4% CMS proposed in July. The site-neutral imaging cut we analyzed last month, however, was finalized intact.
With most provisions effective January 1, 2027, finance teams have about 50 days to turn proposed-rule models into final-rule budgets. Here's what changed between July and November, what it means for the dollars, and where the clinical record decides how much of it you keep
Key Takeaways
CMS issued the CY 2027 OPPS final rule on November 4, 2026; most provisions take effect January 1, 2027 (CMS)
The net payment update is 2.3%: a 3.2% market basket less a 0.9-point productivity cut, down from the 2.4% proposed (CMS)
340B-acquired drugs move from ASP plus 6% to ASP minus 28%, softer than the proposed ASP minus 33.4%, with a budget-neutral 7.5% increase to non-drug payments (CMS; AHA)
The 340B remedy offset on non-drug services rises from 0.5% to 2%, not the proposed 3%, with the $7.8 billion recovery now projected to finish in 2031 (CMS)
Site-neutral payment for non-contrast imaging at excepted off-campus departments is final, an estimated $260 million first-year cut; rural sole community hospitals are exempt (CMS)
Starting January 1, 2028, each off-campus department needs its own NPI and a provider-based attestation to be paid; initial attestations are due by December 31, 2027 (AHA; Bradley Arant)
What Changed Between the Proposed and Final Rule

Per the CMS fact sheet (Nov. 4, 2026) and AHA News (Nov. 4, 2026), the final rule moved on several numbers that matter to a CFO:
Payment update: 2.3% net (3.2% market basket less a 0.9-point productivity cut), versus 2.4% proposed
340B drug rate: ASP minus 28%, versus ASP minus 33.4% proposed; non-340B hospitals stay at ASP plus 6%
Non-drug rate increase: 7.5% to keep the 340B cut budget neutral
Remedy offset: 2% per year starting in 2027, versus 3% proposed and 0.5% today, with full recovery projected for 2031 rather than 2029
Inpatient Only list: 637 services removed, essentially the 638 proposed
AHA News reports that CMS based the final 340B rate on HRSA ceiling price data rather than relying on the acquisition cost survey hospitals criticized. Rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals remain exempt from the 340B rate. The AHA said it remains "deeply concerned about CMS' continued assault on the 340B program," so legal and legislative pressure isn't over.
The 340B Math, Hospital by Hospital

At ASP minus 28%, Medicare pays $72 for every $100 of a 340B drug's ASP, compared with $106 today. That's about 32% less per drug, versus roughly 37% less under the proposal. CMS estimates the policy reduces Original Medicare drug payments by $4.35 billion and beneficiary drug cost-sharing by $1.1 billion in the first year. America's Essential Hospitals (Nov. 6, 2026) puts the combined reduction to 340B hospitals at $5.45 billion.

The budget-neutral 7.5% increase to non-drug items and services softens the blow, but not evenly. As Bradley Arant Boult Cummings notes (Nov. 9, 2026), the actual increase varies by procedure and may not offset lost drug revenue at an individual hospital. Consider a hypothetical 340B hospital billing $10 million of separately payable 340B drugs to Medicare at ASP: its drug payments fall from $10.6 million to $7.2 million, a $3.4 million swing, before any non-drug gain and before the higher offset.
That offset matters too. At 2% instead of 0.5%, a hospital with $50 million in non-drug OPPS payments gives back $1 million a year instead of $250,000. Hospitals that enrolled in Medicare after January 1, 2018 are excluded. The point for the budget: the national 2.3% headline tells you very little. Your number depends on your drug mix, service mix, and enrollment date.
The Imaging Cut Is Final
CMS finalized site-neutral payment for imaging without contrast (X-ray, ultrasound, CT, MRI, and certain bone density scans) furnished in excepted off-campus provider-based departments. Those services will be paid at the Physician Fee Schedule-equivalent rate, which AHA News puts at 40% of the OPPS rate. CMS estimates a $260 million reduction in 2027. Rural sole community hospitals are exempt, and the policy isn't budget neutral, so there's no offsetting redistribution.
If you modeled exposure from our proposed-rule analysis, that model is now your 2027 budget. It also raises the stakes on outpatient denials, which were already outpacing inpatient denials before this cut.
The Inpatient Only phase-out keeps moving, too. Per Bradley Arant, the 637 removals reach well beyond orthopedics into gastrointestinal, urologic, gynecologic, endocrine, and thoracic surgery. Every one of those cases now needs a documented, clinically defensible status decision, and outpatient payment for a case that might have been inpatient shifts both revenue and denial risk.

The 2028 Deadline That Starts Now
Beginning January 1, 2028, Medicare won't pay for services at a covered off-campus outpatient department unless it bills under its own NPI, separate from the main hospital, and the hospital has attested to compliance with provider-based rules. Per Bradley Arant, existing departments must submit initial attestations by December 31, 2027, after obtaining NPIs and updating enrollment records.
That sounds far away. It isn't, if you run dozens of off-campus sites. Each one needs an NPI, updated enrollment, and an evidence file that proves provider-based status. The rule also adds prior authorization for eight more botulinum toxin injection codes starting July 1, 2027, another reason to tighten the prior authorization workflows many hospitals are already rebuilding.
Where Physician-Led Insight Changes the Outcome
Each of these policies ends up in the medical record. Whether a newly outpatient-eligible procedure belongs in an inpatient bed, whether an imaging order supports the site of service, whether a botulinum toxin injection meets prior authorization criteria: auditors and payers will judge all of it against the documentation. RevCure's physician-led teams review charts the way a payer's physician reviewer will, starting with the clinical picture and then the code, so the record supports the status, the site, and the payment.
What to Do in the Next 50 Days
Rerun your 340B model at ASP minus 28%, the 7.5% non-drug increase, and the 2% offset, using 12 months of claims.
Rebuild your 2027 imaging budget at 40% of the OPPS rate for non-contrast studies at excepted off-campus departments.
Inventory every off-campus department and assign an owner for its NPI, enrollment update, and attestation file.
Map the 637 procedures leaving the Inpatient Only list against your surgeons' schedules, and brief physician advisors on status decisions.
Confirm 340B drug modifiers and charge capture are correct before the first January claims go out.

The final rule gives hospitals more room on 340B than the proposal did, and none on imaging or provider-based compliance. A physician-led review now turns that into a budget you can defend.
Frequently Asked Questions About the CY 2027 OPPS Final Rule
1. Is the CY 2027 OPPS rule final?
Yes. CMS issued the CY 2027 OPPS and ASC final rule on November 4, 2026. Most provisions, including the 340B payment change, the higher remedy offset, and the site-neutral imaging policy, take effect January 1, 2027. The off-campus NPI and attestation requirement takes effect January 1, 2028, and prior authorization for additional botulinum toxin codes begins July 1, 2027.
2. How much will 340B drug payments drop in 2027?
CMS finalized payment for 340B-acquired drugs at ASP minus 28%, down from ASP plus 6%. That is about 32% less per dollar of ASP. CMS proposed ASP minus 33.4% in July. CMS estimates Original Medicare drug payments fall $4.35 billion and beneficiary cost-sharing falls $1.1 billion in the first year.
3. Which hospitals are exempt from the 340B payment cut?
Rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals are exempt from the 340B drug payment rate. Critical access hospitals are not paid under OPPS. Hospitals that enrolled in Medicare after January 1, 2018 are excluded from the remedy offset on non-drug services.
4. What is the 340B remedy offset in the final rule?
CMS raised the annual reduction to non-drug OPPS payments from 0.5% to 2% starting in 2027. It had proposed 3%. The offset recovers the $7.8 billion in higher non-drug payments hospitals received while the earlier 340B cuts were in effect, and CMS now projects full recovery in 2031 instead of 2029.
5. Did CMS finalize the site-neutral imaging cut?
Yes. Imaging without contrast, such as X-ray, ultrasound, CT, and MRI, furnished at excepted off-campus provider-based departments will be paid at the Physician Fee Schedule-equivalent rate, about 40% of the OPPS rate. CMS estimates a $260 million reduction in 2027. Rural sole community hospitals are exempt.
6. What is the off-campus NPI and attestation requirement?
Beginning January 1, 2028, each covered off-campus hospital outpatient department must bill under its own NPI, separate from the main hospital, and the hospital must attest to provider-based compliance to receive Medicare payment. Existing departments must submit initial attestations by December 31, 2027, after obtaining NPIs and updating enrollment.
Sources: CMS, "Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule (CMS-1850-F)" fact sheet (Nov. 4, 2026); AHA News, "CMS finalizes increases to Medicare hospital outpatient department payment rates, changes to site-neutral and 340B for 2027" (Nov. 4, 2026); America's Essential Hospitals, "CMS Finalizes 2027 OPPS Rule" (Nov. 6, 2026); Tara Ravi, Bradley Arant Boult Cummings LLP, "2027 OPPS Final Rule: Implications for Outpatient Growth and Healthcare Transactions," National Law Review (Nov. 9, 2026).



Comments